Low molecular weight heparin in unstable coronary artery disease

Expert Opinion on Investigational Drugs

Volumn 9, Issue 3, 2000, Pages 581-592

  Wallentin, L ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antithrombotic treatment; Coronary heart disease; Dalteparin; Enoxaparin; Low molecular weight heparins; Myocardial infarction; Nadroparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN;

BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PATIENT COMPLIANCE; REVASCULARIZATION; REVIEW; THROMBIN TIME; THROMBOSIS;

EID: 0033999467     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.3.581     Document Type: Review

References (40)